- Home
- GALT vs RDIB Comparison
GALT vs RDIB Comparison
Compare GALT & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | RDIB |
|---|---|---|
| Founded | 2000 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.3M | 259.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | RDIB |
|---|---|---|
| Price | $6.13 | $11.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 440.3K | 5.8K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $211,292,000.00 |
| Revenue This Year | N/A | $1.06 |
| Revenue Next Year | N/A | $10.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.73 | $5.78 |
| 52 Week High | $6.66 | $14.95 |
Technical Indicators
Market Signals| Indicator | GALT | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 47.74 |
| Support Level | $5.10 | $11.29 |
| Resistance Level | $6.32 | $12.35 |
| Average True Range (ATR) | 0.52 | 0.54 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 66.03 | 38.90 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.